Celcuity Enters Clinical Trial Collaboration And Supply Agreement With Bayer To Provide Nubeqa For Planned Phase 1b/2 Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Celcuity has entered into a clinical trial collaboration and supply agreement with Bayer. Under the agreement, Bayer will provide Nubeqa for Celcuity's planned Phase 1b/2 clinical trial.
August 22, 2023 | 8:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celcuity's partnership with Bayer for the supply of Nubeqa for its clinical trial could potentially boost its research capabilities and future prospects.
The partnership with Bayer, a major pharmaceutical company, could enhance Celcuity's research capabilities by providing access to Nubeqa for its clinical trial. This could potentially lead to positive outcomes for the trial, boosting Celcuity's future prospects and potentially its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100